LINCOLN PHARMACEUTICALS
|
LINCOLN PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 41.11 | 46.58 | 36.40 | 34.63 | 31.08 |
| CEPS(Rs) | 47.55 | 51.89 | 40.97 | 38.66 | 34.85 |
| DPS(Rs) | 1.80 | 1.80 | 1.50 | 1.50 | 1.50 |
| Book NAV/Share(Rs) | 335.34 | 295.98 | 250.86 | 216.12 | 182.92 |
| Tax Rate(%) | 24.58 | 23.67 | 27.45 | 27.71 | 25.65 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 15.55 | 16.46 | 16.68 | 19.23 | 19.88 |
| EBIT Margin(%) | 17.02 | 20.38 | 19.17 | 19.61 | 19.45 |
| Pre Tax Margin(%) | 16.73 | 20.14 | 18.79 | 19.32 | 19.09 |
| PAT Margin (%) | 12.62 | 15.37 | 13.63 | 13.97 | 14.19 |
| Cash Profit Margin (%) | 14.59 | 17.12 | 15.35 | 15.60 | 15.92 |
| Performance Ratios | |||||
| ROA(%) | 10.64 | 13.70 | 12.24 | 13.31 | 13.48 |
| ROE(%) | 13.02 | 17.04 | 15.59 | 17.35 | 18.32 |
| ROCE(%) | 17.55 | 22.53 | 21.82 | 24.29 | 24.90 |
| Asset Turnover(x) | 0.84 | 0.89 | 0.90 | 0.95 | 0.95 |
| Sales/Fixed Asset(x) | 2.67 | 2.80 | 2.90 | 3.17 | 3.04 |
| Working Capital/Sales(x) | 1.66 | 1.76 | 1.81 | 1.89 | 1.88 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.37 | 0.36 | 0.34 | 0.32 | 0.33 |
| Receivable days | 91.75 | 89.63 | 86.09 | 84.27 | 89.34 |
| Inventory Days | 43.57 | 44.26 | 48.72 | 43.86 | 39.12 |
| Payable days | 141.73 | 110.27 | 124.63 | 138.44 | 126.82 |
| Valuation Parameters | |||||
| PER(x) | 13.42 | 12.57 | 9.31 | 8.98 | 7.23 |
| PCE(x) | 11.60 | 11.28 | 8.27 | 8.04 | 6.45 |
| Price/Book(x) | 1.64 | 1.98 | 1.35 | 1.44 | 1.23 |
| Yield(%) | 0.33 | 0.31 | 0.44 | 0.48 | 0.67 |
| EV/Net Sales(x) | 1.74 | 2.00 | 1.27 | 1.28 | 1.03 |
| EV/Core EBITDA(x) | 8.73 | 8.63 | 5.79 | 5.75 | 4.70 |
| EV/EBIT(x) | 9.74 | 9.38 | 6.30 | 6.23 | 5.12 |
| EV/CE(x) | 1.61 | 1.95 | 1.28 | 1.09 | 0.90 |
| M Cap / Sales | 1.77 | 2.02 | 1.33 | 1.32 | 1.06 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 7.35 | 13.76 | 8.09 | 11.30 | 9.75 |
| Core EBITDA Growth(%) | -7.71 | 20.29 | 5.88 | 13.61 | 21.24 |
| EBIT Growth(%) | -10.21 | 20.68 | 5.26 | 14.20 | 23.15 |
| PAT Growth(%) | -11.74 | 27.99 | 5.11 | 11.41 | 20.95 |
| EPS Growth(%) | -11.74 | 27.99 | 5.11 | 11.41 | 20.84 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 4.00 | 3.94 | 4.07 | 3.37 | 3.46 |
| Quick Ratio(x) | 3.40 | 3.29 | 3.34 | 2.71 | 2.97 |
| Interest Cover(x) | 58.99 | 84.45 | 50.50 | 67.11 | 54.61 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of LINCOLN PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LINCOLN PHARMACEUTICALS | ₹966.0 Cr | -0% | -9.1% | -48.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,708.0 Cr | -2.9% | -1.8% | -2.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹171,975.0 Cr | 2.1% | 0.2% | 9.1% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹128,619.0 Cr | 0.5% | 2.2% | 11.2% | Stock Analytics | |
| CIPLA | ₹122,539.0 Cr | 0.7% | -0.8% | 3.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,741.0 Cr | -0.1% | 2.5% | 2.5% | Stock Analytics | |
LINCOLN PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LINCOLN PHARMACEUTICALS | -0% |
-9.1% |
-48.6% |
| SENSEX | -0.4% |
-0.3% |
3.9% |
You may also like the below Video Courses
